Immunicum Q4 2021: Our comment on the report and strategy update - Redeye

Redeye comments on Immunicum’s Q4 report and the company’s strategy outlook held yesterday evening. Based on the report, the company’s strategy update, and general market conditions we adjust our projections and valuation. We reiterate our positive outlook with the company now having a clear path forward for its clinical-stage projects.

Länk till analysen i sin helhet: https://www.redeye.se/research/833677/immunicum-q4-2021-our-comment-on-the-report-and-strategy-update?utm_source=finwire&utm_medium=RSS